Search

Your search keyword '"Fleischmann, R."' showing total 1,390 results
Start Over Author "Fleischmann, R."
1,390 results on '"Fleischmann, R."'

201. Association of radiographic outcomes with low disease activity and remission, and sustainability of response with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Author

Fleischmann, R, Schiff, M, Weinblatt, M, Maldonado, M, Massarotti, E, Fay, J, and Yazici, Y

Subjects
musculoskeletal diseases, abatacept, ddc: 610, 610 Medical sciences, Medicine, radiographic outcomes
Abstract

Background: Remission and low disease activity (LDA) are now more achievable goals in RA. Data from the AMPLE trial showed comparable rates of remission and LDA for patients treated with subcutaneous (SC) abatacept or adalimumab [ref:1], [ref:2]. We evaluated the relationship of [for full text, please go to the a.m. URL], 42. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 28. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 24. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2014
Full Text
View/download PDF

202. Baricitinib, méthotrexate, ou baricitinib associé au méthotrexate chez les patients ayant une polyarthrite rhumatoïde (PR) récente qui ont reçu peu ou pas de traitements de fond (DMARDs): Résultats de l’essai de phase 3 RA-BEGIN

Author

Fleischmann, R., primary, Takeuchi, T., additional, Schlichting, D., additional, Macias, W., additional, Rooney, T., additional, Gurbuz, S., additional, Stoykov, I., additional, Beattie, S., additional, Kuo, W.L., additional, Schiff, M., additional, and Dougados, M., additional

Published
2016
Full Text
View/download PDF

204. Comparaison du certolizumab pegol versus adalimumab : résultats d’efficacité et de tolérance à 2 ans d’une étude comparative directe de supériorité, en aveugle pour les investigateurs

Author

Chapurlat, R., primary, Fleischmann, R., additional, Burmester, G., additional, Combe, B., additional, Curtis, J., additional, Hall, S., additional, Haraoui, B., additional, Van Vollenhoven, R., additional, Cioffi, C., additional, Ecoffet, C., additional, Ionescu, L., additional, Gervitz, L., additional, Peterson, L., additional, and Smolen, J.S., additional

Published
2016
Full Text
View/download PDF

206. Olokizumab Treatment of both Western and Asian Patients with Rheumatoid Arthritis who have Failed Anti-Tnf Treatment Results in Sustained Improvements in Patient-Reported Outcomes

Author

Genovese, MC, primary, Durez, P, additional, Fleischmann, R, additional, Tanaka, Y, additional, Furst, DE, additional, Yamanaka, H, additional, Vasyutin, I, additional, Kaviarasu, T, additional, Korneva, E, additional, Koloda, D, additional, and Takeuchi, T, additional

Published
2016
Full Text
View/download PDF

210. THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

Author

Lu, P., primary, Fleischmann, R., additional, Curtis, C., additional, Ignatenko, S., additional, Desai, M., additional, Wong, S.L., additional, Grebe, K.M., additional, Zeng, J., additional, Medema, J., additional, and Stolzenbach, J., additional

Published
2016
Full Text
View/download PDF

216. OP0186 Immune Complex Bound U1 and Y1 RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Sysytemic Lupus Erythematosus Patients

Author

Doedens, J., primary, Jones, W., additional, Hill, K., additional, Mason, M., additional, Linsley, P., additional, Mease, P., additional, Dall'Era, M., additional, Aranow, C., additional, Martin, R., additional, Cohen, S., additional, Fleischmann, R., additional, Kivitz, A., additional, Burge, D., additional, Chaussabel, D., additional, Elkon, K., additional, Posada, J., additional, and Gabel, C., additional

Published
2016
Full Text
View/download PDF

219. SAT0148 Improvements in Patient-Reported Outcomes with Olokizumab Treatment in Patients with Active, Moderate To Severe Rheumatoid Arthritis Who Had Failed Previous Anti-TNF Therapy: Results from The Ra0056 Double-Blind, Randomized Controlled Study, and RA0057, Its Open-Label Extension

Author

Genovese, M., primary, Fleischmann, R., additional, Furst, D., additional, Janssen, N., additional, Carter, J., additional, Dasgupta, B., additional, Pitzalis, C., additional, Vasyutin, I., additional, Kaviarasu, T., additional, Krotkova, A., additional, and Durez, P., additional

Published
2016
Full Text
View/download PDF

221. THU0623 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying anti-Rheumatic Drugs: Table 1.

Author

Schiff, M., primary, Takeuchi, T., additional, Gaich, C., additional, DeLozier, A.M., additional, Schlichting, D., additional, Kuo, W.-L., additional, Durez, P., additional, Carmack, T., additional, Won, J.-E., additional, and Fleischmann, R., additional

Published
2016
Full Text
View/download PDF

222. THU0193 Response To Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies: Table 1.

Author

Weinblatt, M., primary, Taylor, P., additional, Tanaka, Y., additional, Keystone, E., additional, Schiff, M., additional, Fleischmann, R., additional, Yang, L., additional, Arora, V., additional, de Bono, S., additional, Holzkaemper, T., additional, Schlichting, D., additional, and Takeuchi, T., additional

Published
2016
Full Text
View/download PDF

223. THU0209 Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in A Phase 3 Study (RA-BEAM): Table 1.

Author

Tanaka, Y., primary, Fleischmann, R., additional, Schiff, M., additional, Takeuchi, T., additional, Keystone, E., additional, Weinblatt, M., additional, Zuckerman, S., additional, Issa, M., additional, Thanabalasundrum, S., additional, Augendre-Ferrante, B., additional, de Bono, S., additional, Schlichting, D., additional, Rooney, T.P., additional, Macias, W.L., additional, and Taylor, P., additional

Published
2016
Full Text
View/download PDF

231. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

Author

Furst, D.E., Keystone, E.C., So, A.K., Braun, J., Breedveld, F.C., Burmester, G.R., Benedetti, F. De, Dorner, T., Emery, P., Fleischmann, R., Gibofsky, A., Kalden, J.R., Kavanaugh, A., Kirkham, B., Mease, P., Rubbert-Roth, A., Sieper, J., Singer, N.G., Smolen, J.S., Riel, P.L. van, Weisman, M.H., and Winthrop, K.L.

Subjects
Evaluation of complex medical interventions Auto-immunity, transplantation and immunotherapy [NCEBP 2]
Abstract

Item does not contain fulltext

Published
2013

234. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.

Author

Lu, P., Fleischmann, R., Curtis, C., Ignatenko, S., Clarke, S. H., Desai, M., Wong, S. L., Grebe, K. M., Black, K., Zeng, J., Stolzenbach, J., and Medema, J. K.

Subjects
*SYSTEMIC lupus erythematosus treatment, *SYSTEMIC lupus erythematosus, *PHARMACODYNAMICS, *BCL-2 proteins, *WOMEN patients, *ADVERSE health care events, *PATIENTS
Abstract

Objective: The anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) may contribute to the pathogenesis of systemic lupus erythematosus. The safety, tolerability, and pharmacodynamics of the selective Bcl-2 inhibitor venetoclax (ABT-199) were assessed in women with systemic lupus erythematosus. Methods: A phase 1, double-blind, randomized, placebo controlled study evaluated single ascending doses (10, 30, 90, 180, 300, and 500mg) and multiple ascending doses (2 cycles; 30, 60, 120, 240, 400, and 600mg for 1 week, and then 3 weeks off per cycle) of orally administered venetoclax. Eligible participants were aged 18-65 years with a diagnosis of systemic lupus erythematosus for 6 months or more receiving stable therapy for systemic lupus erythematosus (which could have included corticosteroids and/or stable antimalarials). Results: All patients (48/48) completed the single ascending dose, 25 continued into the multiple ascending dose, and 44/50 completed the multiple ascending dose; two of the withdrawals (venetoclax 60mg and 600 mg cohorts) were due to adverse events. Adverse event incidences were slightly higher in the venetoclax groups compared with the placebo groups, with no dose dependence. There were no serious adverse events with venetoclax. The most common adverse events were headache, nausea, and fatigue. Venetoclax 600 mg multiple ascending dose treatment depleted total lymphocytes and B cells by approximately 50% and 80%, respectively. Naive, switched memory, and memory B-cell subsets enriched in autoreactive B cells exhibited dose-dependent reduction of up to approximately 80%. There were no consistent or marked changes in neutrophils, natural killer cells, hemoglobin, or platelets. Conclusions: Venetoclax was generally well tolerated in women with systemic lupus erythematosus and reduced total lymphocytes and disease-relevant subsets of antigen-experienced B cells. Registration: ClinicalTrials.gov: NCT01686555. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

250. Bücherschau

Author

Rant, Z., Gersten, K., Dickmann, H. E., Witt, Ernst, Kauderer, H., Brödel, W., Hahnemann, H. W., Anke, K., Zuse, K., Busse, E., Fleischmann, R., Brüner, H., and Hain, K.

Published
1957
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results